Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8114316 | 1.00 | SLC6A3 (0.59) | SLC6A3SIGMAR1HTR1ADRD2ACHE | |
| Hydrochloric Acid SCHEMBL10464381 | 0.98 | SLC6A3 (0.58) | SLC6A3SIGMAR1HTR1ADRD2ACHE | |
| SCHEMBL3958997 | 0.90 | SIGMAR1 (0.66) | SIGMAR1 | |
| SCHEMBL17533381 | 0.83 | SLC6A3 (0.59) | SLC6A3SIGMAR1HTR1ADRD2ACHE | |
| SCHEMBL7270268 | 0.82 | SIGMAR1 (0.61) | SIGMAR1ACHEMEN1KMT2A | |
| SCHEMBL6948856 | 0.80 | GAA (0.40) | SLC6A3SIGMAR1MEN1KMT2A | |
| SCHEMBL5180843 | 0.79 | HRH3 (0.44) | SLC6A3SIGMAR1 | |
| SCHEMBL13150782 | 0.79 | SLC6A3 (0.83) | SLC6A3SIGMAR1HTR1ADRD2ACHE | |
| SCHEMBL14407778 | 0.79 | SLC6A3 (0.83) | SLC6A3SIGMAR1HTR1ADRD2ACHE | |
| SCHEMBL6056974 | 0.79 | SLC6A3 (0.83) | SLC6A3SIGMAR1HTR1ADRD2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3183232-A1 | SUBSTITUTED 1-ARYLETHYL-4-ACYLAMINOPIPERIDINE DERIVATIVES AS OPIOID/ALPHA-ADRENORECEPTOR MODULATORS AND METHOD OF THEIR PREPARATION | The Arizona Board of Regents on behalf of The University of Arizona (US) | 2017-06-28 | — | — | EP | claimed |
| US-20160052882-A1 | Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2016-02-25 | — | — | US | claimed |
| WO-2016029218-A1 | SUBSTITUTED 1-ARYLETHYL-4-ACYLAMINOPIPERIDINE DERIVATIVES AS OPIOID/ALPHA-ADRENORECEPTOR MODULATORS AND METHOD OF THEIR PREPARATION | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2016-02-25 | — | — | WO | claimed |
| US-20250073217-A1 | SMALL MOLECULE ADRENORECEPTOR ANTAGONISTS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-03-06 | — | — | US | disclosed |
| WO-2023133135-A2 | SMALL MOLECULE ADRENORECEPTOR ANTAGONISTS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-3183232-B1 | SUBSTITUTED 1-ARYLETHYL-4-ACYLAMINOPIPERIDINE DERIVATIVES AS OPIOID/ALPHA-ADRENORECEPTOR MODULATORS AND METHOD OF THEIR PREPARATION | UNIV ARIZONA (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3183232-B1 | SUBSTITUTED 1-ARYLETHYL-4-ACYLAMINOPIPERIDINE DERIVATIVES AS OPIOID/ALPHA-ADRENORECEPTOR MODULATORS AND METHOD OF THEIR PREPARATION | UNIV ARIZONA (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11440885-B2 | Substituted 1-arylalkyl-4-acylaminopiperidine compounds and methods of producing and using the same | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERISTY OF ARIZONA (US) | 2022-09-13 | — | — | US | disclosed |
| US-20200222380-A1 | Substituted 1-Arylalkyl-4-Acylaminopiperidine Compounds and Methods of Producing and Using the Same | ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA, A BODY CORPORATE (US) | 2020-07-16 | — | — | US | disclosed |
| US-10617681-B2 | 1-arylalkyl-4-acylaminopiperidine compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190134018-A1 | 1-ARYLALKYL-4-ACYLAMINOPIPERIDINE COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2019-05-09 | — | — | US | disclosed |
| US-6642231-B2 | Antineoplastic agents, treatment for neuronal injury and degeneration | AVENTIS PHARMACEUTICALS INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1056744-B1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMA INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
| US-6479487-B1 | INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| US-4954506-A | ANALGESICS, NARCOTIC ANTAGONISTS | BOC, INC. (US) | 1990-09-04 | — | — | US | disclosed |
| US-4916142-A | N-heterocyclic-N-(4-piperidinyl)amides and pharmaceutical compositions and their use as analgesics | BOC, INC. (US) | 1990-04-10 | — | — | US | disclosed |
| US-4912109-A | Narcotic antagonist | BOC, INC. (US) | 1990-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | CDK6, CDK5, CDK2 | SLC6A3 1347/4885SIGMAR1 4659/4885HTR1A 1989/4885 |
| US-20250073217-A1 | SMALL MOLECULE ADRENORECEPTOR ANTAGONISTS AND USES THEREOF | OPRL1, OPRK1, OPRM1 | SLC6A3 758/4885SIGMAR1 46/4885HTR1A 264/4885 |
| US-20160052882-A1 | Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation | OPRD1, OPRK1, OPRM1 | SLC6A3 566/4885SIGMAR1 15/4885HTR1A 164/4885 |
| US-20200222380-A1 | Substituted 1-Arylalkyl-4-Acylaminopiperidine Compounds and Methods of Producing and Using the Same | HRH4, OPRL1, OPRK1 | SLC6A3 542/4885SIGMAR1 70/4885HTR1A 157/4885 |
| US-20190134018-A1 | 1-ARYLALKYL-4-ACYLAMINOPIPERIDINE COMPOUNDS | NR5A2, NR0B1, NR4A3 | SLC6A3 1669/4885SIGMAR1 294/4885HTR1A 467/4885 |
| US-11440885-B2 | Substituted 1-arylalkyl-4-acylaminopiperidine compounds and methods of producing and using the same | HRH4, OPRL1, OPRK1 | SLC6A3 542/4885SIGMAR1 70/4885HTR1A 157/4885 |
| US-10617681-B2 | 1-arylalkyl-4-acylaminopiperidine compounds | NR5A2, NR0B1, NR4A3 | SLC6A3 1669/4885SIGMAR1 294/4885HTR1A 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.